Interstitial lung disease in systemic sclerosis.

Area of Science:

• Rheumatology
• Pulmonology
• Radiology

Background:

• Interstitial lung disease (ILD) is the primary cause of mortality in systemic sclerosis (SSc), replacing renal crisis.
• The precise pathogenesis of SSc-ILD remains elusive, limiting the efficacy of current treatments.
• Early identification of SSc-ILD is critical due to the benefits of immunomodulatory agents in slowing disease progression.

Purpose of the Study:

• To review the epidemiology, pathogenesis, clinical challenges, and management strategies for SSc-ILD.
• To highlight the importance of early SSc-ILD detection using thoracic high-resolution computed tomography (HRCT).
• To discuss the nuanced decision-making process for initiating treatment based on disease severity and progression.

Main Methods:

• Review of international collaborative data on SSc-ILD.
• Analysis of current understanding of SSc-ILD pathogenesis.
• Evaluation of diagnostic tools, including thoracic HRCT.
• Discussion of clinical management strategies and treatment thresholds.

Main Results:

• SSc-ILD is now the leading cause of death in systemic sclerosis.
• No definitive pathogenic pathway for SSc-ILD has been identified.
• Immunomodulatory agents can slow lung disease progression, underscoring the need for early detection.

Conclusions:

• Early detection of SSc-ILD via HRCT is highly desirable.
• Treatment decisions involve balancing risks and benefits, with a preference for observation in limited disease.
• Treatment initiation is more strongly indicated in severe or rapidly progressing SSc-ILD.